On the Record · Apellis Pharmaceuticals
Apellis Pharmaceuticals competitors, on the record
The companies Apellis Pharmaceuticals itself names as competitors in its annual reports, 2023 to 2025, each with the sentence it appears in and the filing it came from.
Who Apellis Pharmaceuticals names
| Company | Named in |
|---|---|
| Astellas Pharma US Inc. | 2025 |
| AstraZeneca Pharmaceuticals LP | 2025 |
| Novartis | 2025 |
In its own words
Astellas Pharma US Inc.
Word for word“In August 2023, the FDA approved avacincaptad pegol, marketed as Izervay, a complement C5 inhibitor developed by Astellas Pharma US Inc., for the treatment of GA.” 10-K for 2025
AstraZeneca Pharmaceuticals LP
Word for word“The principal competitors for EMPAVELI are eculizumab (marketed as Soliris) and ravulizumab (marketed as Ultomiris), which are C5 inhibitors marketed by AstraZeneca Pharmaceuticals LP, or AstraZeneca.” 10-K for 2025
Novartis
Word for word“Furthermore, in December 2023, the FDA approved iptacopan (marketed as Fabhalta), an orally administered factor B inhibitor developed by Novartis, for the treatment of PNH.” 10-K for 2025
Read from Apellis Pharmaceuticals’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-24. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.